olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimen
Phase 3UNKNOWN 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
Conditions
Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
Trial Timeline
Oct 1, 2020 → Mar 30, 2021
NCT ID
NCT04536558About olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimen
olanzapine plus fosaprepitant-based triple regimen + placebo plus fosaprepitant-based triple regimen is a phase 3 stage product being developed by Sun Pharmaceutical for Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy. The current trial status is unknown. This product is registered under clinical trial identifier NCT04536558. Target conditions include Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04536558 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy
Other Products from Sun Pharmaceutical
Ilumya Injectable ProductApproved
85
CequaTM (Cyclosporine 0.09%) ophthalmic solutionApproved
85
Cyclosporine + Artificial tearApproved
85
AmifostineApproved
85
Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy + Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapyApproved
85